Immunovant reports positive initial Phase 2 data for batoclimab in Graves' disease; IgG reduction up to 87%

Immunovant, Inc.

Initial cohort in Phase 2 trial exceeded 50% response rate; response defined as normalization of T3/T4 without increasing ATD dose.
680 mg SC batoclimab showed IgG reduction up to 87% (mean 81%) after 12 weeks; 340 mg produced lower IgG reductions.
Dose response observed on anti-TSHR autoantibodies and clinical parameters including ATD dose reduction/discontinuation.
Batoclimab generally well tolerated with no new safety signals.
CEO says intent to focus future Graves' development on IMVT-1402, with plans announced later in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.